Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been given an average recommendation of “Buy” by the seven analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.58.

A number of analysts have commented on CRVS shares. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $8.75 target price for the company in a report on Wednesday, November 7th. Cowen reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, November 2nd. BidaskClub cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 21st. Credit Suisse Group raised shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $11.00 to $15.00 in a research report on Wednesday, August 15th. Finally, Wedbush reissued an “outperform” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, August 8th.

CRVS traded down $0.26 during trading on Thursday, reaching $7.25. 94,491 shares of the company’s stock were exchanged, compared to its average volume of 71,815. Corvus Pharmaceuticals has a fifty-two week low of $6.81 and a fifty-two week high of $13.91. The firm has a market capitalization of $231.62 million, a PE ratio of -2.67 and a beta of -0.57.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, November 1st. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. Equities analysts forecast that Corvus Pharmaceuticals will post -1.77 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in CRVS. BlackRock Inc. boosted its position in shares of Corvus Pharmaceuticals by 10.1% during the first quarter. BlackRock Inc. now owns 737,118 shares of the company’s stock worth $8,499,000 after purchasing an additional 67,461 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Corvus Pharmaceuticals by 112.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 134,436 shares of the company’s stock valued at $1,550,000 after acquiring an additional 71,300 shares in the last quarter. Millennium Management LLC lifted its position in Corvus Pharmaceuticals by 925.6% in the 1st quarter. Millennium Management LLC now owns 605,303 shares of the company’s stock valued at $6,979,000 after acquiring an additional 546,286 shares in the last quarter. Acadian Asset Management LLC lifted its position in Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock valued at $236,000 after acquiring an additional 12,119 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at $147,000. 88.61% of the stock is currently owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

See Also: Stop Order

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.